4.

匹配后111例患者OS的单变量和多变量分析

Univariate and multivariate analyses of OS in 111 patients with and without NASIDs use

Characteristics		Univariate	Analysis			Multivariate	Analysis
		HR	95% CI	P		HR	95% CI	P
ECOG PS: Eastern cooperative oncology group performance status; BCLC: Barcelona clinic liver cancer; TACE: Transcatheter arterial chemoembolization; HAIC: Hepatic arterial infusion chemotherapy; AFP: α-fetoprotein.
Age	< 65 vs ≥65	0.914	0.275-3.042	0.883
Gender	Male vs Female	0.494	0.198-1.229	0.129
Hepatitis B	Yes vs No	1.358	0.514-3.588	0.538
Cirrhosis	Yes vs No	1.038	0.481-2.240	0.924
Drink	Yes vs No	0.601	0.227-1.588	0.304
Lymph node metastasis	Yes vs No	0.625	0.264-1.482	0.286
Extrahepatic metastasis	Yes vs No	0.873	0.381-1.999	0.748
Tumor thrombus	Yes vs No	1.675	0.784-3.575	0.183
BCLC stage				0.950				0.308
	B vs A	1.089	0.134-8.870	0.936		0.793	0.261-2.407	0.683
	C vs A	0.945	0.126-7.062	0.956		1.196	0.429-3.340	0.732
ECOG PS	0-1 vs ≥2			0.547		1.836	0.832-4.051	0.133
Child-Pugh	Yes vs No	2.398	1.042-5.517	0.040		1.730	1.010-2.964	0.046
Prior therapy
Targeted Therapy	Yes vs No	1.443	0.648-3.215	0.369
TACE	Yes vs No	0.825	0.388-1.757	0.619
Ablation	Yes vs No	1.022	0.242 -4.327	0.976
Surgical resection	Yes vs No	0.456	0.184-1.130	0.090
HAIC	Yes vs No	2.706	1.010-7.250	0.048		1.674	0.774-3.617	0.190
Subsequent therapy
Targeted Therapy	Yes vs No	0.765	0.358-1.636	0.490
TACE	Yes vs No	0.502	0.190-1.327	0.165
Ablation	Yes vs No	0.047	0-994.653	0.548
HAIC	Yes vs No	1.169	0.493-2.769	0.723
AFP	< 400 vs ≥400	1.620	1.085-2.418	0.018		1.281	0.832-1.972	0.261
NASIDS	Yes vs No	0.552	0.208-1.463	0.232		1.085	0.685-1.717	0.729